• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    BioLineRx Issues Letter to Shareholders

    1/21/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLRX alert in real time by email

    - Company outlines strategic long-term vision and financial outlook -

    TEL AVIV, Israel, Jan. 21, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today issued the following letter to shareholders.

    BioLineRx Ltd. Logo

    To my fellow shareholders,

    It has been approximately two months since we announced a major strategy shift with the signing of an exclusive license agreement with Ayrmid Ltd. to commercialize APHEXDA® (motixafortide), the next-generation stem cell mobilization agent that we successfully shepherded from early clinical development through FDA approval and commercial launch in September 2023. Following such a transformational transaction, I wanted to provide more granularity regarding our vision for our company moving forward, as we remain as committed as ever to maximizing value for our shareholders.

    To fully understand where we plan to go, it is important to recap the salient terms of the license agreement with Ayrmid Ltd. (Ayrmid), as well as the previously announced license agreement that we entered into with Guangzhou Gloria Biosciences Co., Ltd. (GloriaBio). Both agreements provided significant non-dilutive upfront capital, while allowing us to retain upside potential from royalties on future sales of APHEXDA, as well as from potential future commercial and development milestones in the respective territories. We expect these collaborations to provide a growing stream of cash flows into our company over time while we work to rebuild our pipeline with new assets.

    Ayrmid

    The license agreement with Ayrmid, which we announced in November 2024, gives Ayrmid the right to develop and commercialize APHEXDA (motixafortide) across all indications, excluding solid tumor indications, and in all territories other than Asia. In exchange for the license, we received a $10 million upfront payment, and are eligible to receive up to an additional $87 million in potential commercial milestones, plus royalties ranging from 18% to 23% on net sales of APHEXDA. In addition, certain funds managed by Highbridge Capital Management LLC, Ayrmid's principal shareholder, executed a $9 million equity investment in the Company.

    GloriaBio

    The license agreement with GloriaBio, which we first announced in August 2023, gives GloriaBio the right to develop and commercialize motixafortide across all indications in the Asia region, beginning with stem cell mobilization (SCM), followed by pancreatic ductal adenocarcinoma (PDAC). In exchange, we received a $15 million upfront payment, and are eligible to receive up to ~$50 million in potential development and regulatory milestones in China and Japan, as well as up to ~$200 million in potential commercial milestones based on defined sales targets. We are also eligible to receive tiered double-digit royalties on net sales. In addition, a $14.6 million equity investment in the Company was executed here as well.

    BioLineRx 2.0

    As it pertains to BioLineRx, or what I now like to call 'BioLineRx 2.0', we have returned to our roots as a lean drug development company, leveraging the many years of experience and the track record of success that our team brings, as evidenced by our successful development of motixafortide, which we advanced from early-stage clinical development through a successful Phase 3 trial, and culminating with FDA approval in September 2023.

    We have retained the rights to develop motixafortide across all solid tumor indications, in all territories other than Asia, including in pancreatic ductal adenocarcinoma (PDAC), for which an investigator-initiated Phase 2b trial, sponsored by Columbia University, and supported equally by BioLineRx and Regeneron, is ongoing at a relatively minimal cost to BioLineRx. A second Phase 2b trial in PDAC is being planned by GloriaBio, at no cost to us. We expect these pipeline programs to continue to advance without any significant expense to our Company, while providing the potential for a meaningful future upside.

    At the same time, a key component of our strategy moving forward is to in-license additional assets in oncology and/or rare diseases over the next two years that we can advance through clinical development. We have substantial experience in scouting and assessing assets in transactions with back-ended, success-based consideration, which can be acquired or licensed for a modest upfront payment, and with relatively modest and affordable clinical development programs. We are actively working on this initiative and are being presented with many promising opportunities that meet these criteria. Visibility on our progress with this initiative, like most companies, will be minimal until we have a tangible agreement to announce.

    Our longer-term vision is to develop innovative assets with significant potential value whose development costs have been offset by the royalties and milestones from our existing motixafortide partnerships. We aim to continue pursuing new partnerships on these programs to create additional value for our shareholders.

    Strengthened Balance Sheet and Streamlined Cost Structure Provide Runway through H2 2026

    Proceeds from the Ayrmid and GloriaBio transactions, together with the opportunistic $10 million equity financing that we completed in early January and our significantly reduced cost structure (our currently planned operating burn rate going forward is ~$12 million per year) are expected to provide us with a current cash runway to execute upon our goals through the second half of 2026. This includes the relatively minor costs associated with continuing to support the PDAC trials, while also engaging in our planned pipeline expansion activities. Furthermore, it does not take into account any potential revenue upside generated from sales royalties or commercial milestones under our out-licensing agreements that I just described.

    ADS Ratio Change Maintains Nasdaq Listing Compliance

    Finally, to regain compliance with Nasdaq's minimum bid price requirement, we announced just a few days ago our intent to change the ratio of our American Depositary Shares to ordinary shares, from 15 ordinary shares per ADS to 600 ordinary shares per ADS. This is equivalent to a 1-for-40 reverse stock split, and will go into effect on January 30, 2025.

    As we continue to execute on our long-term strategy, including the potential in-licensing of new assets, maintaining our Nasdaq exchange listing is a critical objective. By implementing this change, we hope to regain compliance with all of Nasdaq's applicable requirements, allowing us to continue to enjoy all the benefits that such a listing confers.

    In closing, we are entering 2025 with a renewed focus on innovative drug development within our core competency areas, a strengthened balance sheet with $29.5 million of cash, a very lean cost structure, and a cash runway based on our current operating plan through the second half of 2026. With these strategic actions completed, I believe we are well positioned to create enduring value for our shareholders while introducing novel therapeutics for patients suffering from cancer or rare diseases.

    I am excited about what the future holds for BioLineRx, both for this year and beyond, and I look forward to keeping you apprised of our continued progress, beginning with our fourth quarter 2024 results release in March.

    Thank you for your continued support.

    Sincerely,

    Phil Serlin

    Philip Serlin

    Chief Executive Officer

    About BioLineRx

    BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. (globally, excluding Asia) and Gloria Biosciences (in Asia). BioLineRx is utilizing its end-to-end expertise in development, regulatory affairs, manufacturing and commercialization to advance its innovative pipeline and ensure life-changing discoveries move beyond the bench to the bedside.

    Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on Twitter and LinkedIn.

    Cautionary Note Regarding Forward-Looking Statements

    Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," and "would," and describe opinions about future events. These include statements regarding management's expectations, beliefs and intentions regarding its future prospects, including BioLineRx's cash runway. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress and results of BioLineRx's preclinical studies, clinical trials, and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials; whether BioLineRx's collaboration partners will be able to execute on collaboration goals in a timely manner; whether the clinical trial results for APHEXDA will be predictive of real-world results; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic candidates, including the degree and pace of market uptake of APHEXDA for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients; whether access to APHEXDA is achieved in a commercially viable manner and whether APHEXDA receives adequate reimbursement from third-party payors; BioLineRx's ability to establish, operationalize and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of BioLineRx's expenses, future revenues, capital requirements and its needs for and ability to access sufficient additional financing, including any unexpected costs or delays in the commercial launch of APHEXDA; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry; statements as to the impact of the political and security situation in Israel on BioLineRx's business, which may exacerbate the magnitude of the factors discussed above. These and other factors are more fully discussed in the "Risk Factors" section of BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on March 26, 2024. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.

    CONTACTS:

    United States

    Irina Koffler

    LifeSci Advisors, LLC

    [email protected]

    Israel

    Moran Meir

    LifeSci Advisors, LLC

    [email protected]

    Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg

     

    Cision View original content:https://www.prnewswire.com/news-releases/biolinerx-issues-letter-to-shareholders-302355990.html

    SOURCE BioLineRx Ltd.

    Get the next $BLRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BLRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    - Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- Provides updated and extended cash runway guidance into H1 2027 -- Management to host conference call today, August 14th, at 8:30 am EDT - TEL AVIV, Israel, Aug. 14, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended June 30, 2025, and provided a corporate update. "Since our last quarterly update, we have been acutely focused on evaluating

    8/14/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

    Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 7, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be a

    8/7/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting

    - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year - Poster presentation on Saturday, May 31st TEL AVIV, Israel, May 30, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare disease, today announced that a poster including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois. The CheMo4METPANC trial is evaluating the company's CXCR4 i

    5/30/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLRX
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by BioLineRx Ltd.

    SCHEDULE 13G - BioLineRx Ltd. (0001498403) (Subject)

    8/14/25 4:03:45 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by BioLineRx Ltd.

    6-K - BioLineRx Ltd. (0001498403) (Filer)

    8/14/25 7:10:33 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by BioLineRx Ltd.

    424B5 - BioLineRx Ltd. (0001498403) (Filer)

    7/25/25 4:30:16 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright reiterated coverage on BioLineRx with a new price target

    HC Wainwright reiterated coverage of BioLineRx with a rating of Buy and set a new price target of $19.00 from $22.00 previously

    3/1/21 8:36:34 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright resumed coverage on BioLineRx

    HC Wainwright resumed coverage of BioLineRx with a rating of Buy

    2/23/21 11:53:43 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on BioLine Rx with a new price target

    HC Wainwright & Co. reiterated coverage of BioLine Rx with a rating of Buy and set a new price target of $19.00 from $22.00 previously

    2/23/21 11:24:05 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for APHEXDA issued to BIOLINERX, LTD.

    Submission status for BIOLINERX, LTD.'s drug APHEXDA (ORIG-1) with active ingredient MOTIXAFORTIDE has changed to 'Approval' on 09/08/2023. Application Category: NDA, Application Number: 217159, Application Classification: Type 1 - New Molecular Entity

    9/11/23 2:15:50 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLRX
    Leadership Updates

    Live Leadership Updates

    View All

    Cognyte Elects Two New Board Members to Strengthen Expertise and Drive Growth

    Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025. Having served with the United States Secret Service f

    2/18/25 8:00:00 AM ET
    $ALLT
    $BLRX
    $CGEN
    Computer Communications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors

    Cayman Islands, December 10, 2024 – Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the appointment of Prof. Amnon Peled as an independent director to its Board of Directors. Prof. Peled, a globally recognized authority in stem cell biology, immunology, and cancer therapeutics who has been involved in numerous successful publicly traded bio-pharma companies, will also serve on the Company's audit, compensation, and nominating and corporate governance committees. The Board unanimously approved his appointment, citing his decades of experience in advancing nov

    12/10/24 8:30:00 AM ET
    $BLRX
    $SLXN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

    Experienced Drug Developer Brings Over 15 Years of Clinical Development Industry Knowledge across Multiple Therapeutic Areas and Modalities TEL AVIV, Israel, Jan. 4, 2023 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has appointed Tami Rachmilewitz, M.D., as Chief Medical Officer.  Dr. Rachmilewitz will report to the CEO and lead the Company's clinical and medical functions.  Her appointment is effective today, January 4, 2023. "Tami has tremendous experience across a range of therapeutic areas and drug development modalities," said Philip Serlin, Chief Executive Officer of BioLineRx. 

    1/4/23 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLRX
    Financials

    Live finance-specific insights

    View All

    BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    - Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 -- Provides updated and extended cash runway guidance into H1 2027 -- Management to host conference call today, August 14th, at 8:30 am EDT - TEL AVIV, Israel, Aug. 14, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the quarter ended June 30, 2025, and provided a corporate update. "Since our last quarterly update, we have been acutely focused on evaluating

    8/14/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLineRx to Report Second Quarter 2025 Results on August 14, 2025

    Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 7, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025, before the U.S. markets open. The Company will host a conference call at 8:30 a.m. EDT featuring remarks by Philip Serlin, Chief Executive Officer. To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be a

    8/7/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update

    - Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot phase of ongoing CheMo4METPANC Phase 2b combination trial of motixafortide in PDAC, sponsored by Columbia University, to be presented at upcoming 2025 ASCO Annual Meeting – - APHEXDA performing well under Ayrmid stewardship - - Management to host conference call today, May 27th, at 8:30 am EDT - TEL AVIV, Israel, May 27, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financia

    5/27/25 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by BioLineRx Ltd. (Amendment)

    SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

    2/11/22 6:49:45 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

    2/16/21 4:10:22 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - BioLineRx Ltd. (0001498403) (Subject)

    2/12/21 9:40:57 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care